Advanced

Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur

Geisler, Christian H.; Kolstad, Arne; Laurell, Anna; Jerkeman, Mats LU ; Raty, Riikka; Andersen, Niels S.; Pedersen, Lone B.; Eriksson, Mikael LU ; Nordstrom, Marie and Kimby, Eva, et al. (2012) In British Journal of Haematology 158(3). p.355-362
Abstract
Mantle cell lymphoma (MCL) is a heterogenic non-Hodgkin lymphoma entity, with a median survival of about 5 years. In 2008 we reported the early based on the median observation time of 4 years results of the Nordic Lymphoma Group MCL2 study of frontline intensive induction immunochemotherapy and autologous stem cell transplantation (ASCT), with more than 60% event-free survival at 5 years, and no subsequent relapses reported. Here we present an update after a median observation time of 6.5 years. The overall results are still excellent, with median overall survival and response duration longer than 10 years, and a median event-free survival of 7.4 years. However, six patients have now progressed later than 5 years after end of treatment.... (More)
Mantle cell lymphoma (MCL) is a heterogenic non-Hodgkin lymphoma entity, with a median survival of about 5 years. In 2008 we reported the early based on the median observation time of 4 years results of the Nordic Lymphoma Group MCL2 study of frontline intensive induction immunochemotherapy and autologous stem cell transplantation (ASCT), with more than 60% event-free survival at 5 years, and no subsequent relapses reported. Here we present an update after a median observation time of 6.5 years. The overall results are still excellent, with median overall survival and response duration longer than 10 years, and a median event-free survival of 7.4 years. However, six patients have now progressed later than 5 years after end of treatment. The international MCL Prognostic Index (MIPI) and Ki-67-expression were the only independent prognostic factors. Subdivided by the MIPI-Biological Index (MIPI + Ki-67, MIPI-B), more than 70% of patients with low-intermediate MIPI-B were alive at 10 years, but only 23% of the patients with high MIPI-B. These results, although highly encouraging regarding the majority of the patients, underline the need of a risk-adapted treatment strategy for MCL. The study was registered at as ISRCTN 87866680. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
mantle cell lymphoma, autologous stem cell transplant, high-dose AraC, rituximab, pre-emptive therapy
in
British Journal of Haematology
volume
158
issue
3
pages
355 - 362
publisher
Federation of European Neuroscience Societies and Blackwell Publishing Ltd
external identifiers
  • wos:000306307500008
  • scopus:84863822702
ISSN
0007-1048
DOI
10.1111/j.1365-2141.2012.09174.x
language
English
LU publication?
yes
id
e3739336-eb24-4fa8-8d10-d3711aa82a55 (old id 2994847)
date added to LUP
2012-09-03 07:17:35
date last changed
2017-11-12 03:08:29
@article{e3739336-eb24-4fa8-8d10-d3711aa82a55,
  abstract     = {Mantle cell lymphoma (MCL) is a heterogenic non-Hodgkin lymphoma entity, with a median survival of about 5 years. In 2008 we reported the early based on the median observation time of 4 years results of the Nordic Lymphoma Group MCL2 study of frontline intensive induction immunochemotherapy and autologous stem cell transplantation (ASCT), with more than 60% event-free survival at 5 years, and no subsequent relapses reported. Here we present an update after a median observation time of 6.5 years. The overall results are still excellent, with median overall survival and response duration longer than 10 years, and a median event-free survival of 7.4 years. However, six patients have now progressed later than 5 years after end of treatment. The international MCL Prognostic Index (MIPI) and Ki-67-expression were the only independent prognostic factors. Subdivided by the MIPI-Biological Index (MIPI + Ki-67, MIPI-B), more than 70% of patients with low-intermediate MIPI-B were alive at 10 years, but only 23% of the patients with high MIPI-B. These results, although highly encouraging regarding the majority of the patients, underline the need of a risk-adapted treatment strategy for MCL. The study was registered at as ISRCTN 87866680.},
  author       = {Geisler, Christian H. and Kolstad, Arne and Laurell, Anna and Jerkeman, Mats and Raty, Riikka and Andersen, Niels S. and Pedersen, Lone B. and Eriksson, Mikael and Nordstrom, Marie and Kimby, Eva and Bentzen, Hans and Kuittinen, Outi and Lauritzsen, Grete F. and Nilsson-Ehle, Herman and Ralfkiaer, Elisabeth and Ehinger, Mats and Sundstrom, Christer and Delabie, Jan and Karjalainen-Lindsberg, Marja-Liisa and Brown, Peter and Elonen, Erkki},
  issn         = {0007-1048},
  keyword      = {mantle cell lymphoma,autologous stem cell transplant,high-dose AraC,rituximab,pre-emptive therapy},
  language     = {eng},
  number       = {3},
  pages        = {355--362},
  publisher    = {Federation of European Neuroscience Societies and Blackwell Publishing Ltd},
  series       = {British Journal of Haematology},
  title        = {Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur},
  url          = {http://dx.doi.org/10.1111/j.1365-2141.2012.09174.x},
  volume       = {158},
  year         = {2012},
}